Zinman, B., Tušek, S., Mirošević, G., Goldoni, V., Jurišić Eržen, D., Balaško, A. ... Fitchett, D. (2018). Empagliflozin in women with type 2 diabetes and
cardiovascular disease – an analysis of EMPA-REG
OUTCOME®. Diabetologia (Berlin), 61. (7), 1522-1527. doi: 10.1007/s00125-018-4630-2
Zinman, Bernard, et al. "Empagliflozin in women with type 2 diabetes and
cardiovascular disease – an analysis of EMPA-REG
OUTCOME®." Diabetologia (Berlin), vol. 61, br. 7, 2018, str. 1522-1527. https://doi.org/10.1007/s00125-018-4630-2
Zinman, Bernard, Srećko Tušek, Gorana Mirošević, Vesna Goldoni, Dubravka Jurišić Eržen, Annemarie Balaško, Stjepan Balić, Ema Drvodelić Šunić, Silvija Canecki Varžić i David Fitchett. "Empagliflozin in women with type 2 diabetes and
cardiovascular disease – an analysis of EMPA-REG
OUTCOME®." Diabetologia (Berlin) 61, br. 7 (2018): 1522-1527. https://doi.org/10.1007/s00125-018-4630-2
Zinman, B., et al. (2018) 'Empagliflozin in women with type 2 diabetes and
cardiovascular disease – an analysis of EMPA-REG
OUTCOME®', Diabetologia (Berlin), 61(7), str. 1522-1527. doi: 10.1007/s00125-018-4630-2
Zinman B, Tušek S, Mirošević G, Goldoni V, Jurišić Eržen D, Balaško A, i sur.. Empagliflozin in women with type 2 diabetes and
cardiovascular disease – an analysis of EMPA-REG
OUTCOME®. Diabetologia (Berlin) [Internet]. 2018. [pristupljeno 25.12.2024.];61(7):1522-1527. doi: 10.1007/s00125-018-4630-2
B. Zinman, et al., "Empagliflozin in women with type 2 diabetes and
cardiovascular disease – an analysis of EMPA-REG
OUTCOME®", Diabetologia (Berlin), vol. 61, br. 7, str. 1522-1527, 2018. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:795484. [Citirano: 25.12.2024.]